OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Vetter and Sentry BioPharma establish preferred partnership agreement
Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis.
Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis. According to a statement, the collaboration will "help streamline the path of study drugs from filling laboratory to clinic while safeguarding product integrity".
"Our partnership with Sentry affirms our mutual commitment to helping clients get high-quality products to market quickly and efficiently," said Peter Soelkner, Managing Director of Vetter. "It also affirms Vetter’s commitment to the North American market."
The Chicago facility, which focuses on preclinical to phase II projects, is Vetter’s first facility outside of Germany and is an expansion of Vetter Development Service. It will be operational at the beginning of Q4 2010.
"We’re proud to partner with Vetter," said Jennifer Marcum, CEO of Sentry BioPharma Services. "Both of our companies share the same dedication to the quality and safety of our clients’ products."